Nima Farzan - Apr 3, 2024 Form 4 Insider Report for Kinnate Biopharma Inc. (KNTE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ James P. Reilly, Attorney-in-Fact
Stock symbol
KNTE
Transactions as of
Apr 3, 2024
Transactions value $
$0
Form type
4
Date filed
4/5/2024, 04:55 PM
Previous filing
Jun 8, 2023
Next filing
Jun 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNTE Common Stock Disposed to Issuer -2.19K -100% 0 Apr 3, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNTE Stock Option (right to buy) Disposed to Issuer -1.28M -100% 0 Apr 3, 2024 Common Stock 1.28M $2.57 Direct F2
transaction KNTE Stock Option (right to buy) Disposed to Issuer -437K -100% 0 Apr 3, 2024 Common Stock 437K $5.63 Direct F3
transaction KNTE Stock Option (right to buy) Disposed to Issuer -275K -100% 0 Apr 3, 2024 Common Stock 275K $35.38 Direct F3
transaction KNTE Stock Option (right to buy) Disposed to Issuer -400K -100% 0 Apr 3, 2024 Common Stock 400K $10.03 Direct F3
transaction KNTE Stock Option (right to buy) Disposed to Issuer -750K -100% 0 Apr 3, 2024 Common Stock 750K $6.78 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Nima Farzan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR.
F2 This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option.
F3 This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.